Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JR 441

Next Previous
X
Search
Drug Profile

JR 441

Alternative Names: JR-441

Latest Information Update: 02 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator JCR Pharmaceuticals
  • Class Neuroprotectants; Recombinant fusion proteins
  • Mechanism of Action Heparan sulfate sulfatase replacements; Transferrin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis III
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Mucopolysaccharidosis III

Most Recent Events

  • 31 Oct 2024 Phase-I clinical trials in Mucopolysaccharidosis III (In infants, In children, In adolescents, In adults) in Japan before October 2024 (Parenteral) (jRCT2071240053)
  • 06 Sep 2024 JCR Pharmaceuticals plans a phase I trial for Mucopolysaccharidosis Type IIIA in Japan
  • 03 Sep 2024 The Pharmaceuticals and Medical Devices Agency completes regulatory review of a phase I trial in Mucopolysaccharidosis III in Japan

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top